Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Zi‐xian Liao"'
Publikováno v:
Journal of Biomedical Science, Vol 31, Iss 1, Pp 1-12 (2024)
Abstract Background As of 2020, hepatocellular carcinoma (HCC), a form of liver cancer, stood as the third most prominent contributor to global cancer-related mortality. Combining immune checkpoint inhibitors (ICI) with other therapies has shown prom
Externí odkaz:
https://doaj.org/article/1e8bf9c3487141c995b9d0cdc63fb155
Autor:
Richa Pandey, Feng-Shuo Yang, Vyshnav Punnath Sivasankaran, Yu-Lun Lo, Yi-Ting Wu, Chia-Yu Chang, Chien-Chih Chiu, Zi-Xian Liao, Li-Fang Wang
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 215 (2023)
The blocking of programmed death-ligand 1 (PD-L1) in tumor cells represents a powerful strategy in cancer immunotherapy. Using viral vectors to deliver the cargo for inactivating the PD-L1 gene could be associated with host cell genotoxicity and conc
Externí odkaz:
https://doaj.org/article/22f701b5ce6a4602877afc6a4be617ba
Autor:
Yu-Lun Lo, Yao-Hsing Fang, Yen-Ju Chiu, Chia-Yu Chang, Chih-Hsien Lee, Zi-Xian Liao, Li-Fang Wang
Publikováno v:
Pharmaceutics, Vol 14, Iss 12, p 2594 (2022)
The development of stimuli-responsive polymeric micelles for targeted drug delivery has attracted much research interest in improving therapeutic outcomes. This study designs copolymers responsive to ultraviolet (UV) light and glutathione (GSH). A di
Externí odkaz:
https://doaj.org/article/8ad248bcd01b41bda44b0302aaf378d3
Autor:
Wangta Liu, Yu-Lun Lo, Chin Hsu, Yi-Ting Wu, Zi-Xian Liao, Wen-Jeng Wu, Yi-Jou Chen, Chieh Kao, Chien-Chih Chiu, Li-Fang Wang
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 17, Iss , Pp 477-490 (2019)
Paclitaxel (PTX) is a widely used chemotherapy drug; however, frequent use causes multidrug resistance (MDR), which limits the utility of PTX against advanced non-small-cell lung cancer (NSCLC). PTX-resistant subline (NCI-H23-TXR) was established in
Externí odkaz:
https://doaj.org/article/e34f9531a2724f38967d4448963782e0
Publikováno v:
Drug Discovery Today. 26:2508-2514
Targeted-therapy failure in treating nonsmall cell lung cancer (NSCLC) frequently occurs because of the emergence of drug resistance and genetic mutations. The same mutations also result in aerobic glycolysis, which further antagonizes outcomes by lo
Publikováno v:
ACS omega. 7(27)
Oncolytic virotherapy was approved as a localized treatment for advanced melanoma by the US Food and Drug Administration (FDA) in 2015. Granulocyte macrophage colony stimulating factor (GM-CSF) encoded by clinical virus-infected tumor cells, acting a
Autor:
Yun‐yun Yue, Yi‐chuan Wang, Zi‐xian Liao, Fang‐yuan Hu, Qiu‐yan Liu, Jing Dong, Min Zhong, Ming‐han Chen, Yu‐min Pan, Hui Zhong, Jing Shang
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES. 36(8)
The peripheral benzodiazepine receptor (TSPO/PBR) is highly conserved among different species but with perplexing biochemical functions. Multiple ligands of TSPO show commendable regulatory activities in lots of biological functions, such as neuro-pr
Publikováno v:
Journal of Controlled Release. 324:482-492
Lung cancer is the primary cause of cancer-related death worldwide. 85%–90% of cases are non-small cell lung cancer (NSCLC) which characteristically exhibits altered epidermal growth factor receptor (EGFR) signaling is a major driver pathway. Unfor
Publikováno v:
Biomacromolecules. 21:3342-3352
A novel dual-stimuli cleavable linker containing adjacent UV light-sensitive o-nitrobenzyl ester and GSH-responsive disulfide bonds was first designed and synthesized to increase the responsivity to external stimuli. The functionalized linker was the